GE HealthCare today launched its AI Innovation Lab, an initiative aimed at accelerating early-stage AI projects within the company. These efforts are part of GE HealthCare’s broader AI and digital strategy, which focuses on integrating AI into medical devices, developing AI tools to support decision-making across healthcare, and leveraging AI to improve outcomes and operational efficiencies. The company’s investment in cloud technology supports these initiatives by providing the computational power necessary to scale AI solutions.
“The AI Innovation Lab showcases our cutting-edge work in healthcare innovation. At GE HealthCare, we’re not just developing technology but exploring novel ways AI can transform healthcare,” said Dr. Taha Kass-Hout, GE HealthCare’s Global Chief Science and Technology Officer. “Projects like Health Companion demonstrate how AI can bring the collective expertise of a multi-disciplinary medical team directly to clinicians, empowering them with actionable insights. The innovations we’re unveiling today are only the beginning, enabled by our advanced AI and cloud computing capabilities. We will continue to gather feedback from customers as we refine these tools to turn health data into strategies that enhance care.”
GE HealthCare’s AI research is focused on improving clinicians’ daily experiences by enhancing diagnostic accuracy, reducing administrative burdens, and ensuring personalized care for every patient. Some key projects include:
- Health Companion: This project explores whether agentic AI, driven by specialized agents in areas like genomics and radiology, can help streamline decision-making and deliver more personalized care. The goal is for these agents to collaborate, analyze multi-modal data, and adapt treatment plans in real time, helping clinicians differentiate between expected treatment symptoms and disease progression.
- Triple-Negative Breast Cancer Recurrence: In collaboration with the Winship Cancer Institute at Emory University, GE HealthCare is using deep learning to analyze multi-modal data to predict the recurrence of triple-negative breast cancer, one of the most aggressive subtypes. This research aims to improve patient outcomes by enabling earlier and more accurate predictions of recurrence.
- Maternal and Infant Care: GE HealthCare is developing AI solutions to address preventable risks during childbirth. By integrating generative AI, the company is creating tools that reduce the time spent searching for data and best practices, while generating patient summaries to support care transitions.
- Multi-modal X-ray Foundation Model: This project involves building a full-body foundation model using a dataset of 1.2 million anonymized X-ray images. The model aims to automate report generation, interpret images into text, and reduce the cognitive burden on healthcare professionals, ultimately improving diagnostic workflows.
- Mammography Screenings: GE HealthCare is developing a cloud-based AI tool to help radiologists quickly identify normal mammograms, allowing them to focus on suspicious cases. This project aims to improve efficiency and accuracy in breast cancer screenings amid a global shortage of radiologists.
GE HealthCare is also working on AI solutions that are closer to market readiness. For example, the company has submitted a 510(k) application to the U.S. FDA for an AI-powered fetal heart rate interpretation tool designed to analyze fetal heart rates and assist care teams in assessing the baby’s health during pregnancy.
These projects reflect GE HealthCare’s 125-year history of innovation, combined with the agility of a start-up, as the company continues to address the healthcare industry’s most pressing challenges. With over 80 FDA AI device authorizations in the last three years, GE HealthCare remains a leader in advancing AI-enabled healthcare technologies.
For more information, visit GE HealthCare at booth #3816 at HLTH 2024 in Las Vegas from October 20-23 or online at https://www.gehealthcare.com.
